J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mai, I.
Right arrow Articles by Roots, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mai, I.
Right arrow Articles by Roots, I.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PHARMACOGENETICS

MDR1 Haplotypes Do Not Affect the Steady-State Pharmacokinetics of Cyclosporine in Renal Transplant Patients

Ingrid Mai, MD, Elke Störmer, PhD, Mark Goldammer, Andreas Johne, MD, Hagen Krüger, MD, Klemens Budde, MD and Ivar Roots, MD

From the Institute of Clinical Pharmacology (Dr. Mai, Dr. Störmer, Mr. Goldammer, Dr. Johne, Dr. Krüger, Dr. Roots) and the Department of Internal Medicine and Nephrology (Dr. Budde), University Medical Center Charité, Humboldt University of Berlin, Berlin, Germany.

This retrospective study investigated the impact of MDR1 haplotypes derived from the single-nucleotide polymorphisms (SNPs) 2677G>T (exon 21) and 3435C>T (exon 26) on the pharmacokinetics of cyclosporine in 98 renal transplant patients. Based on SNPs 2677 and 3435, four different haplotypes and nine different genotypes were identified in the study sample. Frequencies of SNPs, genotypes, and haplotypes were in agreement with previously reported values. Cyclosporine pharmacokinetics were characterized using a 2-hour AUC (AUC0-12), trough concentrations (C0), and blood concentrations 2 hours after cyclosporine administration (C2). No significant differences in dose-corrected AUC0-12, C0, or C2 values were observed between carriers of different SNP variants and genotypes (Kruskal-Wallis test), as well as between carriers and noncarriers of each haplotype (Mann-Whitney U test). Carriers of haplotype 12 (2677G and 3435T), which has previously been associated with increased digoxin AUC values, had a median AUC0-12 of 18.9 µg•h•L-1 (range: 9.0-35.2) compared to 17.5 µg•h•L-1 (range: 7.5-37.1) in the noncarrier group. It was concluded that MDR1 haplotypes derived from the SNPs 2677G>T (exon 21) and 3435C>T (exon 26) are not associated with cyclosporine pharmacokinetics in renal transplant patients.


Key Words: P-glycoproteinMDR1haplotypecyclosporinepharmacokineticspatients

Address for reprints: Dr. Ingrid Mai, Institut für Klinische Pharmakologie der Charité, Humboldt-Universität zu Berlin, Schumannstr. 20/21, 10098 Berlin, Germany.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Journal of Pharmacy PracticeHome page
D. S. Streetman
Clinical Pharmacogenetics of the Major Adenosine Triphosphate Binding Cassette and Solute Carrier Drug Transporters
Journal of Pharmacy Practice, June 1, 2007; 20(3): 219 - 233.
[Abstract] [PDF]


Home page
Am J Health Syst PharmHome page
K. N. Utecht, J. J. Hiles, and J. Kolesar
Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors
Am. J. Health Syst. Pharm., December 1, 2006; 63(23): 2340 - 2348.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
S.-J. Lee, W. J. Jusko, C. G. Salaita, K. A. Calis, M. W. Jann, V. E. Spratlin, J. A. Goldstein, and Y. Y. Hon
Reduced Methylprednisolone Clearance Causing Prolonged Pharmacodynamics in a Healthy Subject Was Not Associated With CYP3A5*3 Allele or a Change in Diet Composition.
J. Clin. Pharmacol., May 1, 2006; 46(5): 515 - 526.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
H. Zheng, E. Schuetz, A. Zeevi, J. Zhang, K. McCurry, S. Webber, A. Iacono, J. Lamba, and G. J. Burckart
Sequential Analysis of Tacrolimus Dosing in Adult Lung Transplant Patients With ABCB1 Haplotypes
J. Clin. Pharmacol., April 1, 2005; 45(4): 404 - 410.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Clinical Pharmacology